ArticleJournal of neurology2007
Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
Article in Journal of neurology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Glatiramer acetate for multiple sclerosis.The Cochrane database of systematic reviews · 2010Pooled it
- Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database.Scientific reports · 2025Article
- A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe.Therapeutic advances in chronic disease · 2025Review
- Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives.Clinical and experimental medicine · 2023Review
- Drug-induced liver injury by glatiramer acetate leading to liver transplant: A case report.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.Current journal of neurology · 2023Article
- Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility.International journal of molecular sciences · 2023Review
- The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.CNS drugs · 2021Review
- Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis.Iranian journal of neurology · 2018Review
- Liver injury and glatiramer acetate, an uncommon association: case report and literature review.Therapeutic advances in neurological disorders · 2017Review
- Article
- Acute hepatitis induced by glatiramer acetate.BMJ case reports · 2009Article
- Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
17351724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.